槲皮素 3,4'-二葡糖甙 | 29125-80-2

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 黄酮类化合物
• 中文名称: 槲皮素 3,4'-二葡糖甙
• 中文别名: 槲皮素-3,4'-二-O-葡糖苷；槲皮素3,4'-二葡糖甙
• 英文名称: 4′-O-β-D-glucopyranosyl-quercetin-3-O-β-D-glucopyranoside
• 英文别名: quercetin 3,4′-di-O-β-D-glucopyranoside；quercetin 3,4'-di-O-β-D-glucopyranoside；isorhamnetin 4',3-di-β-D-diglucoside；quercetin-3,4'-di-O-β-D-glucoside；quercetin 3,4'-O-β-D-diglucoside；quercetin 3,4'-O-diglucoside；Quercetin 3,4'-diglucoside；5,7-dihydroxy-2-[3-hydroxy-4-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]-3-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromen-4-one
• CAS: 29125-80-2
• 化学式: C₂₇H₃₀O₁₇
• 分子量: 626.525
• InChiKey: RPVIQWDFJPYNJM-DEFKTLOSSA-N

物化性质

• 熔点：
  185-189℃
• 沸点：
  1029.3±65.0 °C(Predicted)
• 密度：
  1.89±0.1 g/cm3 (20 ºC 760 Torr)
• 溶解度：
  DMSO（轻微）、吡啶（轻微、超声处理）、水（非常轻微）

计算性质

• 辛醇/水分配系数(LogP)：
  -1.4
• 重原子数：
  44
• 可旋转键数：
  7
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  286
• 氢给体数：
  11
• 氢受体数：
  17

安全信息

• WGK Germany：
  3

反应信息

• 作为产物：
  描述：

  芦丁 在 盐酸 、 palladium 10% on activated carbon 、 氢气 、 sodium methylate 、 potassium carbonate 作用下， 以 四氢呋喃 、 甲醇 、 乙醇 、 水 、 N,N-二甲基甲酰胺 为溶剂， 20.0~80.0 ℃ 、100.0 kPa 条件下， 反应 50.0h， 生成 槲皮素 3,4'-二葡糖甙
  参考文献：
  名称：

  Synthesis of quercetin glycosides and their melanogenesis stimulatory activity in B16 melanoma cells

  摘要：

  4'-O-beta-D-Glucopyranosyl-quercetin-3-O-beta-D-glucopyranosyl-(1 -> 4)-beta-D-glucopyra-noside (3) was isolated from Helminthostachys zeylanica root extract as a melanogenesis acceleration compound and was synthesized using rutin as the starting material. Related compounds were also synthesized to understand the structure-activity relationships in melanin biosynthesis.Melanogenesis activities of the glycosides were determined by measuring intracellular melanin content in B16 melanoma cells. Among the synthesized quercetin glycosides, quercetin-3-O-beta-D-glucopyranoside (1), quercetin-3-O-beta-D-glucopyranosyl-(1 -> 4)-beta-D-glucopyranoside (2), and 3 showed more potent intracellular melanogenesis acceleration activities than theophyline used as positive control in a dose-dependent manner with no cytotoxic effect. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2013.12.062

文献信息

• Glycosynthases from Thermotoga neapolitana β-glucosidase 1A: A comparison of α-glucosyl fluoride and in situ-generated α-glycosyl formate donors
  作者：Tania Pozzo、Merichel Plaza、Javier Romero-García、Magda Faijes、Eva Nordberg Karlsson、Antoni Planas

  DOI：10.1016/j.molcatb.2014.05.021

  日期：2014.9

  constructed to evaluate their glycosynthase activity towards oligosaccharide synthesis. Two approaches were used for the synthesis reactions, both of which utilized 4-nitrophenyl β-d-glucopyranoside (4NPGlc) as an acceptor molecule: the first using an α-glucosyl fluoride donor at low temperature (35 °C) in a classical glycosynthase reaction, and the second by in situ generation of the glycosyl donor with

  来自嗜热嗜热菌Theromotoga neapolitana的Tn Bgl1A是一种二聚体β-葡萄糖苷酶，属于糖苷水解酶家族1（GH1），具有通过保留机制的水解活性，并且对β-1,4-，β-1具有广泛的底物特异性，一系列糖寡糖上的3-和β-1,6-键。该酶的三种变体（Tn Bgl1A_E349G，Tn Bgl1A_E349A和TnBgl1A_E349S），在催化亲核试剂上发生突变，用于评估其对寡糖合成的糖合酶活性。有两种方法用于合成反应，两种方法均使用4-硝基苯基β-d-吡喃葡萄糖苷（4NPGlc）作为受体分子：第一种方法是在经典糖合酶的低温（35°C）下使用α-葡萄糖基氟化物供体反应，第二步是用（4NPGlc）原位生成糖基供体，其中甲酸在较高温度（70°C）下充当外源亲核试剂。使用第一种方法Tn Bgl1A_E349G和TnBgl1A_E349A经过长时间孵育（15小时）后，以良好的产率（高达61％）合成了具有β-1
• Coatings for implantable medical devices
  申请人：Sahajanand Medical Technologies PVT. ltd

  公开号：EP1832301A2

  公开（公告）日：2007-09-12

  The present invention relates to a composition comprising at least one polymer covalently bonded to heparin, and at least one pharmaceutically active agent other than heparin dispersed within the at least one polymer, a medical device coated with the composition and uses thereof. In a preferred embodiment, the active agent is paclitaxel, genistein or rapamycin (sirolimus). The medical device is preferably a drug eluting stent.

  本发明涉及一种组合物，该组合物包括至少一种与肝素共价键合的聚合物、至少一种分散在至少一种聚合物中的除肝素以外的药用活性剂、涂有该组合物的医疗器械及其用途。 在一个优选的实施方案中，活性剂是紫杉醇、染料木素或雷帕霉素（西罗莫司）。 医疗设备最好是药物洗脱支架。
• Compositions and coatings for implantable medical devices
  申请人：Sahajanand Medical Technologies PVT. ltd

  公开号：EP1832289A2

  公开（公告）日：2007-09-12

  A composition comprising at least one polymer, heparin, and at least one pharmaceutically active agent selected from Formula A, Formula B, LY294002, and LY303511 having the formulae

  一种组合物，包含至少一种聚合物、肝素和至少一种选自式 A、式 B、LY294002 和 LY303511 的药物活性剂，其式为
• Compositions comprising porous articles and uses in implantable medical devices
  申请人：Sahajanand Medical Technologies PVT. ltd

  公开号：EP1834636A1

  公开（公告）日：2007-09-19

  The present invention relates to a composition comprising a first polymer having pores, nanoparticles dispersed within the pores of the first polymer, the nanoparticles comprising a second polymer and at least one pharmaceutically active agent dispersed in the second polymer; and heparin covalently bonded to at least one of the first and second polymer. The invention further relates to medical devices coated with the composition and uses thereof. In a preferred embodiment, the invention relates to a stent coated with porous heparinized poly-l-lactic acid or heparinized PVP. Active agents are chosen from paclitaxel, rapamycin, genistein, flavonoid, LY294002 or LY303511 (both benzopyran-4-one compounds).

  本发明涉及一种组合物，该组合物包括具有孔隙的第一种聚合物、分散在第一种聚合物孔隙中的纳米颗粒，纳米颗粒包括第二种聚合物和分散在第二种聚合物中的至少一种药用活性剂；以及与第一种和第二种聚合物中的至少一种共价键合的肝素。本发明还涉及涂有该组合物的医疗器械及其用途。 在一个优选的实施方案中，本发明涉及一种涂有多孔肝素化聚乳酸或肝素化 PVP 的支架。活性剂选自紫杉醇、雷帕霉素、染料木素、黄酮、LY294002 或 LY303511（均为苯并吡喃-4-酮化合物）。
• Composition comprising cannabinoids for relief of pain
  申请人：CANOPY HEALTH INNOVATIONS

  公开号：US11110069B2

  公开（公告）日：2021-09-07

  The present technology generally relates to compositions comprising cannabinoids for relieving pain in a subject and to methods of using such compositions for relieving pain in a subject.

  本技术一般涉及用于缓解受试者疼痛的包含大麻素的组合物，以及使用此类组合物缓解受试者疼痛的方法。